Obligatory information that a patient diagnosed of prostate cancer and candidate for an active surveillance protocol must know;Información obligatoria que debe conocer un paciente con cáncer de próstata candidato a vigilancia activa

Actas Urologicas Espanolas

Volumn 38, Issue 9, 2014, Pages 559-565

  Rubio Briones, J ^a   Iborra, I ^a   Ramirez M ^a   Calatrava, A ^a   Collado, A ^a   Casanova, J ^a   Dominguez Escrig J ^a   Gomez Ferrer A ^a   Ricos J V ^a   Monros J L ^a   Dumont, R ^a   Lopez Guerrero J A ^a   Salas, D ^b   Solsona, E ^a  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b Subdirección Asistencial   (Spain)

Author keywords

Active surveillance; Information; Patients; Prognostic; Prostate cancer

Indexed keywords

ADULT; AGED; CLINICAL PROTOCOL; HUMAN; MALE; MIDDLE AGED; PATIENT EDUCATION; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; WATCHFUL WAITING;

ADULT; AGED; CLINICAL PROTOCOLS; HUMANS; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; WATCHFUL WAITING;

EID: 84908313033     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acuro.2014.02.007     Document Type: Article

References (23)

1. C.J. Savage, H. Lilja, A.M. Cronin, D. Ulmert, and A.J. Vickers Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening Cancer Epidemiol Biomarkers Prev 19 2010 1201 1207
2. J. Rubio-Briones, J. Casanova, R. Dumont, L. Rubio, A. Fernandez-Serra, and I. Casanova-Salas Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program Actas Urol Esp 2013 doi:pii: S0210-4806(13)00333-1. 10.1016/j.acuro.2013.09.007
3. J.M. Cozar, B. Miñana, F. Gomez-Veiga, A. Rodriguez-Antolín, H. Villavicencio, and A. Cantalapiedra [National prostate cancer registry 2010 in Spain] Actas Urol Esp 37 2013 12 19
4. A. Heidenreich, P.J. Bastian, J. Bellmunt, M. Bolla, S. Joniau, and T. van der Kwast EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent-update 2013 Eur Urol 65 2014 124 137
5. G.S. Sandhu, and G.L. Andriole Active surveillance for prostate cancer: Barriers to widespread adoption Eur Urol 62 2012 984 985
6. J.I. Epstein, P.C. Walsh, M. Carmichael, and C.B. Brendler Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368 374
7. M. Bul, X. Zhu, R. Valdagni, T. Pickles, Y. Kakehi, and A. Rannikko Active surveillance for low-risk prostate cancer worldwide: The PRIAS study Eur Urol 63 2013 597 603
8. R.A. Godtman, E. Holmberg, A. Khatami, J. Stranne, and J. Hugosson Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Goteborg randomised population-based prostate cancer screening trial Eur Urol 63 2013 101 107
9. C. Blazquez, V. Hernandez, E. de la Peña, F.J. Diaz, M.D. Martin, and J.M. de la Morena Oncological outcomes in patients potentially eligible for active surveillance who underwent radical prostatectomy Actas Urol Esp 37 2013 603 607
10. V. Hernandez, C. Blazquez, E. de la Peña, E. Perez-Fernandez, F.J. Diaz, and C. Llorente Active surveillance in low-risk prostate cancer. Patient acceptance and results Actas Urol Esp 37 2013 533 537
11. T.A. Stamey, F.S. Freiha, J.E. McNeal, E.A. Redwine, A.S. Whittemore, and H.P. Schmid Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer Cancer 71 3 Suppl 1993 933 938
12. T. Wolters, M.J. Roobol, P.J. van Leeuwen, R.C. van den Bergh, R.F. Hoedemaeker, and G.J. van Leenders A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial J Urol 185 2011 121 125
13. C.J. Kane, R. Im, C.L. Amling, J.C. Presti Jr., W.J. Aronson, and M.K. Terris Outcomes after radical prostatectomy among men who are candidates for active surveillance: Results from the SEARCH database Urology 76 2010 695 700
14. J.R. Palisaar, J. Noldus, B. Loppenberg, C. von Bodman, F. Sommerer, and T. Eggert Comprehensive report on prostate cancer misclassification by 16 currently used low-risk and active surveillance criteria BJU Int 110 6 Pt B 2012 E172 E181
15. L.M. Wong, S.M. Alibhai, G. Trottier, N. Timilshina, T. van der Kwast, and A. Zlotta A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression Eur Urol 2013 10.1016/j.eururo.2013.04.038
16. V. Iremashvili, M. Manoharan, D.L. Rosenberg, and M.S. Soloway Biopsy features associated with prostate cancer progression in active surveillance patients: Comparison of three statistical models BJU Int 111 2012 574 579
17. G. Ploussard, E. Xylinas, L. Salomon, Y. Allory, D. Vordos, and A. Hoznek The role of biopsy core number in selecting prostate cancer patients for active surveillance Eur Urol 56 2009 891 898
18. J.I. Epstein, W.C. Allsbrook Jr., M.B. Amin, and L.L. Egevad The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Am J Surg Pathol 29 2005 1228 1242
19. H.M. Ross, O.N. Kryvenko, J.E. Cowan, J.P. Simko, T.M. Wheeler, and J.I. Epstein Do adenocarcinomas of the prostate with Gleason score (GS) ≤ 6 have the potential to metastasize to lymph nodes? Am J Surg Pathol 36 2012 1346 1352
20. L. Klotz, L. Zhang, A. Lam, R. Nam, A. Mamedov, and A. Loblaw Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2009 126 131
21. E.A. Singer, A. Kaushal, B. Turkbey, A. Couvillon, P.A. Pinto, and H.L. Parnes Active surveillance for prostate cancer: Past, present and future Curr Opin Oncol 24 2012 243 250
22. M.A. Dall'Era, P.C. Albertsen, C. Bangma, P.R. Carroll, H.B. Carter, and M.R. Cooperberg Active surveillance for prostate cancer: A systematic review of the literature Eur Urol 62 2012 976 983
23. M.R. Cooperberg, P.R. Carroll, and L. Klotz Active surveillance for prostate cancer: Progress and promise J Clin Oncol 29 2011 3669 3676